A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

por Atkins, Susan, Detke, Holland C, McDonnell, David P, Case, Michael G, Wang, Shufang
Publicado 2014

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

por Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly
Publicado 2019

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

por Chen, Jian, Ascher-Svanum, Haya, Nyhuis, Allen W, Case, Michael G, Phillips, Glenn A, Schuh, Kory J, Hoffmann, Vicki Poole
Publicado 2011

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

por Loo, Li Shen, Plato, Brian M., Turner, Ira M., Case, Michael G., Raskin, Joel, Dowsett, Sherie A., Krege, John H.
Publicado 2019

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

por Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
Publicado 2018

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

por Schwarz, Adam J., Sundell, Karen L., Charil, Arnaud, Case, Michael G., Jaeger, Ralf K., Scott, David, Bracoud, Luc, Oh, Joonmi, Suhy, Joyce, Pontecorvo, Michael J., Dickerson, Bradford C., Siemers, Eric R.
Publicado 2019